Archives of Clinical Infectious Diseases

Published by: Kowsar

A Surveillance on Protease Inhibitor Resistance-Associated Mutations Among Iranian HIV-1 Patients

Zeynab Nasiri-Tajabadi 1 , Farah Bokharaei Salim 2 , Mohammad-Javad Najafzadeh 3 , 4 , Saeed Kalantari 5 , Saba Garshasbi 6 , Saeid Amel Jamehdar 1 , 7 , Hadi Farsiani 1 , 7 , Zahra Mazaheri 1 , Mojtaba Sankian 8 and Masoud Youssefi 1 , 7 , *
Authors Information
1 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Virology, Iran University of Medical Sciences, Tehran, Iran
3 Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Cancer Molecular Pathology Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Departments of Infectious Diseases and Tropical Medicine, Iran University of Medical Sciences, Tehran, Iran
6 HIV Laboratory of National Center, Deputy of Health, Iran University of Medical Sciences, Tehran, Iran
7 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
8 Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Archives of Clinical Infectious Diseases: December 31, 2018, 13 (6); e69153
  • Published Online: September 26, 2018
  • Article Type: Research Article
  • Received: April 7, 2018
  • Revised: July 4, 2018
  • Accepted: July 8, 2018
  • DOI: 10.5812/archcid.69153

To Cite: Nasiri-Tajabadi Z, Bokharaei Salim F, Najafzadeh M, Kalantari S, Garshasbi S , et al. A Surveillance on Protease Inhibitor Resistance-Associated Mutations Among Iranian HIV-1 Patients, Arch Clin Infect Dis. 2018 ; 13(6):e69153. doi: 10.5812/archcid.69153.

Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, et al. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Ctries. 2009;3(5):380-91. [PubMed: 19759509].
  • 2. Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005;192(6):967-73. doi: 10.1086/432763. [PubMed: 16107948].
  • 3. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 2003;17(16):2383-8. doi: 10.1097/01.aids.0000076341.42412.59. [PubMed: 14571191].
  • 4. DiazGranados CA, Mantilla M, Lenis W. Antiretroviral drug resistance in HIV-infected patients in Colombia. Int J Infect Dis. 2010;14(4):e298-303. doi: 10.1016/j.ijid.2009.05.006. [PubMed: 19665910].
  • 5. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: Scientific principles and clinical applications. Drugs. 2012;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. [PubMed: 22686620]. [PubMed Central: PMC3689909].
  • 6. Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch Virol. 2017;162(6):1477-85. doi: 10.1007/s00705-017-3228-1. [PubMed: 28181034].
  • 7. Hirsch MS. HIV drug resistance--a chink in the armor. N Engl J Med. 2002;347(6):438-9. doi: 10.1056/NEJMe020072. [PubMed: 12167687].
  • 8. Shafer RW, Kantor R, Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2000;2(4):211-28. [PubMed: 19096725]. [PubMed Central: PMC2604813].
  • 9. Dayer MR, Dayer MS. Whiskers-less HIV-protease: A possible way for HIV-1 deactivation. J Biomed Sci. 2013;20:67. doi: 10.1186/1423-0127-20-67. [PubMed: 24024748]. [PubMed Central: PMC3847613].
  • 10. Brik A, Wong CH. HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem. 2003;1(1):5-14. [PubMed: 12929379].
  • 11. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685-92. doi: 10.1097/QAD.0b013e32802ef30c. [PubMed: 17413689].
  • 12. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: A randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283(4):492-8. [PubMed: 10659875].
  • 13. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet. 2006;368(9534):476-82. doi: 10.1016/S0140-6736(06)69155-1. [PubMed: 16890834].
  • 14. Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, et al. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr. 2011;56(2):109-17. doi: 10.1097/QAI.0b013e3181fe946e. [PubMed: 21107269].
  • 15. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A. 2006;103(46):17355-60. doi: 10.1073/pnas.0607274103. [PubMed: 17065321]. [PubMed Central: PMC1622926].
  • 16. Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JA, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8(8). e71972. doi: 10.1371/journal.pone.0071972. [PubMed: 23977189]. [PubMed Central: PMC3747072].
  • 17. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608-18. doi: 10.1086/503914. [PubMed: 16652319]. [PubMed Central: PMC2547473].
  • 18. Baesi K, Ravanshad M, Ghanbari Safari M, Saberfar E, Hajiabdolbaghi M. [Survey of human immunodeficiency virus-1 protease gene drug resistance among HIV-infected patients in an Iranian research center for HIV/AIDS]. Pathobiol Res. 2012;14(4):13-20. Persian.
  • 19. Hamkar R, Mohraz M, Lorestani S, Aghakhani A, Truong HM, McFarland W, et al. Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients. AIDS. 2010;24 Suppl 2:S85-91. doi: 10.1097/01.aids.0000386738.32919.67. [PubMed: 20610954].
  • 20. Naziri H, Tabarraei A, Ghaemi A, Davarpanah MA, Javid N, Moradi A. [Drug- Resistance- Associated Mutations and HIV Sub-Type Determination in Drug-Naive and HIV-Positive Patients under Treatment with Antiretroviral Drugs]. Med Lab J. 2013;7(3):1-8. Persian.
  • 21. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14(1):17-27. [PubMed: 22297501].
  • 22. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18(14):1965-6. [PubMed: 15353986].
  • 23. Grossman Z, Schapiro JM, Levy I, Elbirt D, Chowers M, Riesenberg K, et al. Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. PLoS One. 2014;9(1). e86239. doi: 10.1371/journal.pone.0086239. [PubMed: 24475093]. [PubMed Central: PMC3903498].
  • 24. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: Mutation patterns and baseline correlates. J Virol. 2005;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005. [PubMed: 15731227]. [PubMed Central: PMC1075714].
  • 25. Monno L, Saracino A, Scudeller L, Pastore G, Bonora S, Cargnel A, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr. 2003;33(4):439-47. [PubMed: 12869832].
  • 26. Luis Jimenez J, Resino S, Martinez-Colom A, Bellon JM, Angeles Munoz-Fernandez M; Spanish Group of Paediatric H.I.V. Infection. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. J Antimicrob Chemother. 2005;56(6):1081-6. doi: 10.1093/jac/dki356. [PubMed: 16195257].
  • 27. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132-3. [PubMed: 28208121]. [PubMed Central: PMC5677049].
  • 28. Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, et al. Unravelling the complex resistance pathways of darunavir using bioinformatics resistance determination (BIRD). Antivir Ther. 2007;12. S141.
  • 29. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6-14. [PubMed: 23596273].
  • 30. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16(1):62-8. [PubMed: 18441382].
  • 31. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One. 2013;8(4). e61864. doi: 10.1371/journal.pone.0061864. [PubMed: 23626742]. [PubMed Central: PMC3633940].
  • 32. Baesi K, Moallemi S, Farrokhi M, Alinaghi SA, Truong HM. Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013. PLoS One. 2014;9(9). e105098. doi: 10.1371/journal.pone.0105098. [PubMed: 25188443]. [PubMed Central: PMC4154867].
  • 33. Soheilli ZS, Ataiee Z, Tootian S, Zadsar M, Amini S, Abadi K, et al. Presence of HIV-1 CRF35_AD in Iran. AIDS Res Hum Retroviruses. 2009;25(1):123-4. doi: 10.1089/aid.2008.0199. [PubMed: 19182925].
  • 34. Baesi K, Moradbeigi M, Ravanshad M, Baghban A. Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran. Asian Pac J Trop Biomed. 2016;6(5):451-4. doi: 10.1016/j.apjtb.2015.12.020.
  • 35. Gholami M, Sadeghi L, Baesi K, Rouzbahani NH, Mohraz M. Survey of antiretroviral drug resistance pattern among HIV-infected patients with treatment failure in Iran. J Hum Virol Retrovir. 2015;3(1):1-6.
  • 36. Naziri H, Baesi K, Moradi A, Aghasadeghi MR, Tabarraei A, McFarland W, et al. Antiretroviral drug resistance mutations in naive and experienced patients in Shiraz, Iran, 2014. Arch Virol. 2016;161(9):2503-9. doi: 10.1007/s00705-016-2955-z. [PubMed: 27368990].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments